Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

920P - Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&E slides


10 Sep 2022


Poster session 10


Laboratory Diagnostics;  Immunotherapy

Tumour Site

Colon and Rectal Cancer


Magali Svrcek


Annals of Oncology (2022) 33 (suppl_7): S417-S426. 10.1016/annonc/annonc1061


M. Svrcek1, C. Saillard2, R. Dubois2, N. Loiseau2, P. Mespoulhe3, F. Brulport2, J. Guillon2, M. Auffret2, M. Sefta2, A. Kamoun2, P. Courtiol2, S. Rossat3, F. Renaud4, A. Fouillet2, G. Wainrib2

Author affiliations

  • 1 Department Of Pathology, Saint-Antoine Hospital, Sorbonne Université, AP-HP, 75012 - Paris/FR
  • 2 Owkin, Owkin France, Paris/FR
  • 3 Medipath, Medipath France, Fréjus/FR
  • 4 Institute Of Pathology, CHU Lille - Lille University Hospital, Lille/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 920P


MisMatch Repair deficiency (dMMR) / Microsatellite instability (MSI) is a crucial biomarker in colorectal cancer (CRC) predictive of response to immunotherapy and Lynch syndrome. Universal screening of newly diagnosed CRC for dMMR/MSI status is now recommended. With the growing numbers of biomarkers screened in clinical practice, dMMR/MSI testing, currently diagnosed by immunohistochemistry (IHC) and/or polymerase chain reaction (PCR), contributes to increasing pathologists workload and delaying therapeutic decisions. Artificial intelligence (AI) models detecting MSI tumors directly from H&E slides have shown promise in improving MSI patients' diagnosis. MSIntuit, an AI-based pre-screening tool developed by Owkin for MSI detection from H&E whole slide images (WSI) of surgical resection specimens from patients with CRC, outputs if the patient is likely to be MSI and should get further testing or not. In this study, we performed a one-shot blind validation of MSIntuit on a large external cohort of WSI from consecutive CRC.


H&E WSI of 600 consecutive resected CRC (including n=123 dMMR/MSI cases) diagnosed at Medipath pathology laboratories in 2017/2018 were studied. dMMR status was assessed using IHC for the 4 MMR proteins, and confirmed by PCR for doubtful cases. Slides were digitized with 2 scanners (Phillips UFS, Roche DP200) and 30 dMMR/MSI WSI were used to calibrate the tool on each scanner. To assess performance in the most robust way, inference was done on the remaining 570 patients blinded to their status. Automated quality check (QC) discarded WSI that did not meet the tool requirements (large blurry/artifact regions, too few tumor tissue).


QC led to the exclusion of 5% / 2% of WSI digitized with DP200 / UFS scanners, respectively. MSIntuit reached sensitivity/specificity of 0.97 [0.93-1.0] / 0.46 [0.42-0.5] on DP200 scanner and 0.95 [0.9-0.98] / 0.47 [0.43-0.51] on UFS scanner.


We performed the first successful blind validation of an AI-based tool for MSI detection from H&E WSI. MSIntuit reaches sensitivity comparable to gold standard methods (92-95%) while reducing almost by 40% the number of patients to screen with standard techniques, paving the way for MSIntuit use in clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





M. Svrcek: Financial Interests, Personal, Advisory Role, Consulting or Advisory Role: BMS, Astellas, MSD Oncology, Sanofi; Financial Interests, Personal, Other, Travel, accommodations, expenses: BMS, Ventana/Roche; Financial Interests, Personal, Advisory Role, Consulting: Owkin. C. Saillard, R. Dubois, N. Loiseau, F. Brulport, J. Guillon, M. Auffret, M. Sefta, A. Fouillet: Financial Interests, Institutional, Full or part-time Employment: Owkin; Financial Interests, Institutional, Stocks/Shares: Owkin. A. Kamoun: Financial Interests, Institutional, Stocks/Shares: Owkin. P. Courtiol: Financial Interests, Institutional, Stocks/Shares: Owkin. S. Rossat: Financial Interests, Institutional, Full or part-time Employment: Medipath. F. Renaud: Financial Interests, Personal, Advisory Role: BMS, MSD. G. Wainrib: Financial Interests, Institutional, Leadership Role: Owkin; Financial Interests, Institutional, Full or part-time Employment: Owkin; Financial Interests, Institutional, Ownership Interest: Owkin. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.